Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

Table 2 Cost-effectiveness ratio under different circumstances and at different ages of vaccination

	60 years*	*65 years*	*70 year*	*75 years*	*80 years*
*Base case*	€38519	€31228	€21716	€24336	€34449
No prevention of death	€38901	€31489	€21910	€25020	€35930
No daytime visits hospital	€38540	€31251	€21731	€24351	€34458
No discounting	€33305	€27482	€18827	€21688	€31285
Discounting 3.5%/3.5%	€45313	€36210	€25647	€27874	€38725
Vaccine price €60 per dose	€30045	€24658	€17163	€19228	€27304
Vaccine price €50 per dose	€25061	€20793	€14485	€16224	€23100
Application costs €9.60**	€40911	€33083	€23002	€25778	€36466
Duration protection 4.8 years***	€61247	€48828	€27817	€32449	€42428
Duration protection 16.1 years***	€16954	€15031	€14030	€16013	€25953

* indirect costs included (loss of working hours, only relevant for vaccination at 60 years of age)
** full influenza tariff (instead of half the influenza tariff €4.80, that was used in the base case)
*** based on van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9):1454-67.

ISSN: 1472-6963